Following on from information provided to NICE by the company in July 2015, the appraisal of Colorectal cancer (metastatic) - MABp1 (after previous treatment) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- TA
- ID number:
- 917
Email enquiries
If you have any queries please email scheduling@nice.org.uk
- External Assessment Group:
- Kleijnen Systematic Reviews Ltd
Stakeholders
- Companies sponsors
- Xbiotech (MABp1)
- Others
- Department of Health
- NHS England
- NHS Hull CCG
- NHS North Kirklees CCG
- Welsh Government
- Patient carer groups
- Beating Bowel Cancer
- Bowel Cancer Information
- Bowel Cancer UK
- Cancer Black Care
- Cancer Equality
- Colostomy Association
- HAWC
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- IA: lleostomy and Internal Pouch Support Group
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie Cancer Care
- Muslim Council of Britain
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- Professional groups
- Association of Anaesthetists
- Association of Cancer Physicians
- Association of Coloproctology of Great Britain and Ireland
- Association of Surgeons of Great Britain and Ireland
- BASO – The Association for Cancer Surgery
- British Geriatrics Society
- British Institute for Radiology
- British Psychosocial Oncology Society
- British Society of Gastroenterology
- Cancer Research UK
- Pelican Cancer Foundation
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- UK Health Forum
- Associated public health groups
- Public Health England
- Public Health Wales
- General commentators
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Commercial Medicines Unit
- NHS Confederation
- Scottish Medicines Consortium
- Relevant research groups
- Bowel & Cancer Research
- Clinical Research Trials Unit
- Cochrane Colorectal Cancer Group
- CORE (Digestive Disorders Foundation)
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in July 2015, the appraisal of Colorectal cancer (metastatic) - MABp1 (after previous treatment) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 27 March 2018 | Suspended. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion recommending the refusal of the marketing authorisation for this drug in this indication. This appraisal will therefore remain suspended. |
| 07 November 2016 | Suspended, The company have not made a submission to NICE. We are discussing the next steps with the company. |
| 20 May 2016 | Draft scope documents |
| 13 May 2016 | Referral |
| 05 April 2016 | Invitation to participate |
For further information on our processes and methods, please see our CHTE processes and methods manual